Company:Excision BioTherapeutics
From HandWiki
Short description: American biotechnology company
| Type | Privately held company |
|---|---|
| Industry |
|
| Founded | January 2015 in San Francisco, California, United States |
| Founders |
|
| Headquarters | US |
Area served | Worldwide |
| Website | excision |
Excision BioTherapeutics is a biopharmaceutical company based in San Francisco focused on developing gene therapies against HIV infection.
The company has a single, CRISPR–Cas9 based therapy, EBT-101, under invesigation. Initial investigation into the therapy was conducted by the lab of Kamel Khalili, a professor at Temple University.[1][2][3][4] In July, 2023 the US Food and Drug Administration granted EBT-101 fast-track status.[5]
References
- ↑ Sheldon, Cormac (30 October 2023). "Armed with gene technologies and CAR-Ts, scientists are attempting to eliminate viruses that escape immune detection and lurk in tissues for years.". Nature Medicine. doi:10.1038/s41587-023-02022-0. https://www.nature.com/articles/s41587-023-02022-0. Retrieved 16 November 2023.
- ↑ "The first human study has launched to treat HIV patients with CRISPR. The CEO of the gene-editing startup says it could be a one-time cure.". Business Insider. 27 January 2023. https://www.businessinsider.com/excision-starts-crispr-gene-editing-trial-for-hiv-patients-2022-1.
- ↑ Brzyski, Laura (5 March 2023). "Excision BioTherapeutics Has Secured $60M to Proceed with HIV Clinical Trial". Philadelphia. https://www.phillymag.com/healthcare-news/2021/03/05/excision-biotherapeutics-temple-hiv-clinical-trial/.
- ↑ Krieger, Lisa (28 October 2023). "CRISPR gene editing could kill HIV. But is it a cure?". The Mercury News. https://www.mercurynews.com/2023/10/28/crispr-could-kill-hiv-but-is-it-a-cure/.
- ↑ Leuty, Ron (21 July 2023). "S.F. biotech inches closer to potential HIV cure with key move by FDA". San Francisco Business Times. https://www.bizjournals.com/sanfrancisco/news/2023/07/20/hiv-aids-cure-crispr-jennifer-doudna-excision.html.
 |  |
